Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.

Abstract: A power supply system 1 includes: first power lines (21p, 21n) to which a first battery (B1) is connected; second power lines (31p, 31n) to which a second battery (B2) is connected; a voltage converter (5) which converts voltage; a power converter which converts electric power; a management ECU (71) and converter ECU (73) which operates the voltage converter (5); a smoothing capacitor connected to the first power lines (21p, 21n); and a motor ECU (72) which executes system interruption processing of determining the existence of failure of the contactors (22m, 22s, 32m, 32s) based on a change in voltage of the smoothing capacitor. The management ECU (71) and converter ECU (73) operate the voltage converter (5) so that a state in which the static voltage of the first battery (B1) is higher by at least the determination potential difference than the static voltage of the second battery (B2).

Abstract: An airbag device with a horn switch body, configured so as to be installed in an upper surface side in a boss portion near a center of a steering wheel, includes: an airbag which inflates by receiving inflation gas; an inflator for supplying inflation gas to the airbag; a pad covering the folded airbag: a mounting base made of sheet metal which holds the airbag, the inflator, and the pad; a horn switch body having an assembling pin to be assembled to a main body side of the steering wheel; and a support plate made of a sheet metal which supports the horn switch body as a configuration attached to a lower surface side of the mounting base. A case around the assembling pin, the mounting base, or the support plate is provided with a spacer capable of preventing rattling of the switch disposition portion in the case.

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract: A rubber composition contains: at least one rubber component selected from the group consisting of an ethylene propylene diene rubber, a chloroprene rubber, a nitrile rubber, and an acrylic rubber; 1.5 to 30 parts by mass of a fluorene-modified cellulose nanofiber per 100 parts by mass of the rubber component; and 30 to 120 parts by mass of a carbon-based filler per 100 parts by mass of the rubber component. A method of producing a rubber composition comprises: kneading a dispersion of a fluorene-modified cellulose nanofiber in a process oil and a rubber component to prepare a kneaded material; and mixing a vulcanizing agent into the kneaded material.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract: An electronic-device having an intermediate connection layer interposed between a wiring substrate and an electronic component. The intermediate connection layer has a laminated structure including a rigid substrate and a flexible substrate. A first conductor part is formed on one principal surface of the flexible substrate, and second and third conductor parts are formed on both principal surfaces of the rigid substrate, respectively. The rigid substrate includes an opening, and the first conductor part of the flexible substrate includes a narrowed fuse part at a position opposite the opening. Windows are formed near the fuse part. The flexible substrate and the rigid substrate are electrically connected with each other via solder.

Abstract: A method for manufacturing a resin pipe joint with a joint body includes the following steps. Preparing a mold and a supply device configured to supply molten resin. The mold includes a first mold for an outer shape of the joint body and a second mold for an inner shape of the joint body. Combining the second mold with the first mold to form a cavity, into which the molten resin is injectable, inside the mold. Supplying the molten resin to the cavity in the mold. Solidifying the molten resin in the cavity after stop of the supply of the molten resin from the supply device. The second mold has a gap that connects the cavity to a discharge space outside the cavity and allows gas to flow.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH? or —N?, or a salt thereof.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: An in-vehicle communication system includes vehicle control devices and a communication management device connected to a network. The communication management device includes: an abnormality detection unit that detects an abnormality and a kind of the abnormality on the basis of reception information received from any one of the vehicle control devices during communication between the vehicle control devices; an abnormality notification unit that notifies the other vehicle control devices of the kind of the abnormality in correspondence with the kind of the abnormality; and a transmission control unit that transmits the reception information to the other vehicle control devices in correspondence with the kind of the abnormality. The vehicle control devices execute a predetermined control in correspondence with the kind of the abnormality that is given in notification from the communication management device.

Abstract: An intermediate connection layer interposed between a wiring substrate and an electronic part includes a rigid substrate and a flexible substrate. A plurality of conductor portions are formed on opposed principal surfaces of the respective flexible and rigid substrates. The rigid substrate is provided with an opening, and a fuse portion on the flexible substrate faces the opening. The flexible substrate and the rigid substrate are bonded together with solders. The respective rigid and flexible substrates are separately made, solder pastes are applied to the rigid substrate, both substrates are overlaid on each other, and the solder pastes are heated and solidified to make the intermediate connection layer.